Since December 2019, severe acute respiratory syndrome coronavirus 2 has been found to be the culprit in the coronavirus disease 2019 (COVID-19), causing a global pandemic. Despite the existence of many vaccine programs, the number of confirmed cases and fatalities due to COVID-19 is still increasing. Furthermore, a number of variants have been reported. Because of the absence of approved anti-coronavirus drugs, the treatment and management of COVID-19 has become a global challenge. Under these circumstances, drug repurposing is an effective method to identify candidate drugs with a shorter cycle of clinical trials. Here, we summarize the current status of the application of drug repurposing in COVID-19, including drug repurposing based on virtual computer screening, network pharmacology, and bioactivity, which may be a beneficial COVID-19 treatment.

自 2019 年 12 月以来，已发现严重急性呼吸系统综合症冠状病毒 2 是 2019 年冠状病毒病 (COVID-19) 的罪魁祸首，导致全球大流行。尽管存在许多疫苗计划，但因 COVID-19 导致的确诊病例和死亡人数仍在增加。此外，已经报道了许多变体。由于缺乏获批的抗冠状病毒药物，COVID-19 的治疗和管理已成为全球性挑战。在这种情况下，药物再利用是确定临床试验周期较短的候选药物的有效方法。在这里，我们总结了药物再利用在 COVID-19 中的应用现状，包括基于虚拟计算机筛选、网络药理学和生物活性的药物再利用，